Biohaven's orally dissolving tablet meets in Phase III for acute migraine

Biohaven's orally dissolving tablet meets in Phase III for acute migraine

Source: 
BioCentury
snippet: 

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) added $8.66 (25%) to $42.65 on Monday after reporting that its orally dissolving tablet (ODT) formulation of rimegepant met the co-primary endpoints in the Phase III BHV3000-303 trial for the acute treatment of migraine.